Plus therapeutics to present positive foresee clinical trial summary demonstrating utility of cnside™ cerebrospinal fluid assay in diagnosis and clinical management of patients with leptomeningeal metastases

Prospective foresee trial of cnside cerebrospinal fluid (csf) assay met key primary and secondary endpoints cnside csf assay influenced clinical management decisions in over 90% of leptomeningeal metastases (lm) cases assay demonstrated 2.8 times the diagnostic sensitivity vs. standard cytology austin, texas, nov. 22, 2024 (globe newswire) -- cnside diagnostics, llc, a wholly owned subsidiary of plus therapeutics, inc. (nasdaq: pstv) (“plus” or the “company”), will present data from the foresee trial showcasing the cnside csf assay platform's utility in diagnosing and guiding clinical decision making for breast cancer and non-small cell lung cancer patients with lm.
pstv Ratings Summary
pstv Quant Ranking